Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Rheumatoid Arthritis & Psoriatic Arthritis | Access and Reimbursement | Indication-Specific Pricing | US | 2017
Two of the largest pharmacy benefits managers (PBMs) in the United States, Express Scripts and CVS Health, have set traditional U.S. drug reimbursement on its head by introducing indication-…
Clostridium Difficile Infections | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017
Market Outlook: Many cases of hospital-acquired infections and healthcare-associated illnesses are attributable to C. difficile infection (CDI). Although standard-of-care antibiotics are…
Graft-Versus-Host Disease | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2017
Graft versus host disease (GVHD) is a potentially life-threatening complication of allogenic hematopoietic stem-cell transplants (HSCTs). The systemic inflammatory reaction is triggered by donor T…
Biosimilars | Emerging Biosimilars | Truxima Launch Tracker | Germany | Wave 1 | 2017
In April 2017, Truxima (rituximab), Celltrion’s biosimilar of Roche’s MabThera, became the first oncology monoclonal antibody (MAb) biosimilar to enter the European market. In this series, we…
Non-Small-Cell Lung Cancer | Access and Reimbursement | Brazil and Mexico | 2017
Non-small-cell lung cancer (NSCLC) affects thousands of individuals in Brazil and Mexico, and it is managed with premium-priced targeted agents and chemotherapy. In both countries, public coverage…
Atopic Dermatitis/Atopic Eczema | Treatment Algorithms: Claims Data Analysis | Pediatric | US | 2018
Atopic dermatitis (AD) is a chronic, pediatric-onset, inflammatory skin disease marked principally by pruritus and eczema. Topical agents (e.g., corticosteroids) are the mainstays of prescription…
Acute Coronary Syndrome | Access and Reimbursement | Accountable Care Organizations | US | 2017
Introduction: This research explores the reimbursement and utilization landscape for acute coronary syndrome (ACS) drugs and the impact of accountable care organizations (ACOs) on payers’ and…